Issues related to developing cell therapies for patients, including Stiff Person Syndrome, rare disease, and Multiple Sclerosis; Issues related to appropriations report language for Fiscal Year 2027.
2026 · 1st Quarter (Jan 1 - Mar 31)
KYVERNA THERAPEUTICS, INC.
Filed by AKIN GUMP STRAUSS HAUER & FELD.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- AKIN GUMP STRAUSS HAUER & FELD
- Filing UUID
- 48d02fb4-216c-4a09-bbf3-5a49815a2559
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.